CIBC Asset Management Inc trimmed its stake in Shire PLC (NASDAQ:SHPG) by 12.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,862 shares of the biopharmaceutical company’s stock after selling 536 shares during the quarter. CIBC Asset Management Inc’s holdings in Shire PLC were worth $591,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Seizert Capital Partners LLC increased its holdings in Shire PLC by 13.3% in the third quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock worth $1,652,000 after buying an additional 1,267 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Shire PLC by 2.9% in the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after buying an additional 1,619 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Shire PLC by 63.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock worth $2,941,000 after buying an additional 6,917 shares during the last quarter. Baldwin Investment Management LLC increased its holdings in Shire PLC by 1.4% in the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 23 shares during the last quarter. Finally, Oak Ridge Investments LLC increased its holdings in Shire PLC by 3.2% in the second quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock worth $13,389,000 after buying an additional 2,528 shares during the last quarter. 18.64% of the stock is owned by institutional investors and hedge funds.

Shares of Shire PLC (NASDAQ SHPG) opened at $147.37 on Monday. The stock has a market cap of $44,273.93, a price-to-earnings ratio of 10.14, a PEG ratio of 0.82 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire PLC has a 52 week low of $137.17 and a 52 week high of $192.15.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The company’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.17 EPS. research analysts expect that Shire PLC will post 15 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Shire PLC (SHPG) Shares Sold by CIBC Asset Management Inc” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/11/20/shire-plc-shpg-shares-sold-by-cibc-asset-management-inc.html.

A number of equities analysts recently commented on the company. Piper Jaffray Companies set a $159.00 price objective on Shire PLC and gave the stock a “hold” rating in a report on Wednesday, July 26th. Royal Bank Of Canada set a $213.00 price objective on Shire PLC and gave the stock a “buy” rating in a report on Friday, August 4th. Cantor Fitzgerald restated a “buy” rating and issued a $222.00 price objective on shares of Shire PLC in a report on Thursday, September 14th. Jefferies Group LLC restated a “hold” rating and issued a $206.00 price objective (down previously from $216.00) on shares of Shire PLC in a report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $212.18.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.